Literature DB >> 16434404

Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules.

Betty Reinboth1, John Thomas, Eric Hanssen, Mark A Gibson.   

Abstract

Recombinant human beta ig-h3 was found to bind 125I-labeled small leucine-rich proteoglycans (SLRPs), biglycan, and decorin, in co-immunoprecipitation experiments. In each instance the binding could be blocked by an excess of the unlabeled proteoglycan, confirming the specificity of the interaction. Scatchard analysis showed that biglycan bound beta ig-h3 more avidly than decorin with Kd values estimated as 5.88 x 10(-8) and 1.02 x 10(-7) M, respectively. In reciprocal blocking experiments both proteoglycans inhibited the others binding to beta ig-h3 indicating that they may share the same binding site or that the two binding sites are in close proximity on the beta ig-h3 molecule. Since beta ig-h3 and the SLRPs are known to be associated with the amino-terminal region of collagen VI in tissue microfibrils, the effects of including collagen VI in the incubations were investigated. Co-immunoprecipitation of 125I-labeled biglycan incubated with equimolar mixtures of beta ig-h3 and pepsin-collagen VI was increased 6-fold over beta ig-h3 alone and 3-fold over collagen VI alone. Similar increases were also observed for decorin. The findings indicate that beta ig-h3 participates in a ternary complex with collagen VI and SLRPs. Static light scattering techniques were used to show that beta ig-h3 rapidly forms very high molecular weight complexes with both native and pepsin-collagen VI, either alone or with the SLRPs. Indeed beta ig-h3 was shown to form a complex with collagen VI and biglycan, which appeared to be much more extensive than that formed by beta ig-h3 with collagen VI and decorin or those formed between the collagen and beta ig-h3, biglycan, or decorin alone. Biglycan core protein was shown to inhibit the extent of complexing of beta ig-h3 with native and pepsin-collagen VI suggesting that the glycosaminoglycan side chains of the proteoglycan were important for the formation of the large ternary complexes. Further studies showed that the direct interaction between beta ig-h3 and biglycan and between biglycan and collagen VI were also important for the formation of these complexes. The globular domains of collagen VI also appeared to have an influence on the interaction of the three components. Overall the results indicate that beta ig-h3 can differentially modulate the aggregation of collagen VI with biglycan and decorin. Thus this interplay is likely to be important in tissues such as cornea where such complexes are considered to occur.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16434404     DOI: 10.1074/jbc.M511316200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Dissection of the human multipotent adult progenitor cell secretome by proteomic analysis.

Authors:  Gregory G Burrows; Wouter Van't Hof; Laura F Newell; Ashok Reddy; Phillip A Wilmarth; Larry L David; Amy Raber; Annelies Bogaerts; Jef Pinxteren; Robert J Deans; Richard T Maziarz
Journal:  Stem Cells Transl Med       Date:  2013-08-27       Impact factor: 6.940

2.  Protein Levels and Microstructural Changes in Localized Regions of Early Cartilage Degeneration Compared with Adjacent Intact Cartilage.

Authors:  Bincy Jacob; Mia Jüllig; Martin Middleditch; Leo Payne; Neil Broom; Vijayalekshmi Sarojini; Ashvin Thambyah
Journal:  Cartilage       Date:  2018-11-28       Impact factor: 4.634

3.  Comparative proteomic analysis of normal and collagen IX null mouse cartilage reveals altered extracellular matrix composition and novel components of the collagen IX interactome.

Authors:  Bent Brachvogel; Frank Zaucke; Keyur Dave; Emma L Norris; Jacek Stermann; Münire Dayakli; Manuel Koch; Jeffrey J Gorman; John F Bateman; Richard Wilson
Journal:  J Biol Chem       Date:  2013-03-24       Impact factor: 5.157

Review 4.  Soluble biglycan as a biomarker of inflammatory renal diseases.

Authors:  Louise Tzung-Harn Hsieh; Madalina-Viviana Nastase; Jinyang Zeng-Brouwers; Renato V Iozzo; Liliana Schaefer
Journal:  Int J Biochem Cell Biol       Date:  2014-08-01       Impact factor: 5.085

Review 5.  Periostin and TGF-β-induced protein: Two peas in a pod?

Authors:  Deane F Mosher; Mats W Johansson; Mary E Gillis; Douglas S Annis
Journal:  Crit Rev Biochem Mol Biol       Date:  2015-08-10       Impact factor: 8.250

6.  Proteomic profiling of TGFBI-null mouse corneas reveals only minor changes in matrix composition supportive of TGFBI knockdown as therapy against TGFBI-linked corneal dystrophies.

Authors:  Ebbe Toftgaard Poulsen; Kasper Runager; Nadia Sukusu Nielsen; Marie V Lukassen; Karen Thomsen; Paige Snider; Olga Simmons; Henrik Vorum; Simon J Conway; Jan J Enghild
Journal:  FEBS J       Date:  2017-11-23       Impact factor: 5.542

7.  Characterization of proteoglycan production and processing by chondrocytes and BMSCs in tissue engineered constructs.

Authors:  J T Connelly; C G Wilson; M E Levenston
Journal:  Osteoarthritis Cartilage       Date:  2008-02-21       Impact factor: 6.576

8.  Targeted glycoproteomic identification of biomarkers for human breast carcinoma.

Authors:  Karen L Abbott; Kazuhiro Aoki; Jae-Min Lim; Mindy Porterfield; Rachelle Johnson; Ruth M O'Regan; Lance Wells; Michael Tiemeyer; Michael Pierce
Journal:  J Proteome Res       Date:  2008-02-14       Impact factor: 4.466

9.  Expression analysis of human pterygium shows a predominance of conjunctival and limbal markers and genes associated with cell migration.

Authors:  C J Jaworski; M Aryankalayil-John; M M Campos; R N Fariss; J Rowsey; N Agarwalla; T W Reid; N Dushku; C A Cox; D Carper; G Wistow
Journal:  Mol Vis       Date:  2009-11-20       Impact factor: 2.367

10.  The matricellular functions of small leucine-rich proteoglycans (SLRPs).

Authors:  Rosetta Merline; Roland M Schaefer; Liliana Schaefer
Journal:  J Cell Commun Signal       Date:  2009-10-02       Impact factor: 5.782

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.